<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02750904</url>
  </required_header>
  <id_info>
    <org_study_id>IR File# 8363</org_study_id>
    <nct_id>NCT02750904</nct_id>
  </id_info>
  <brief_title>Web-Delivered Acceptance &amp; Commitment Therapy for Smokers With Bipolar Disorder</brief_title>
  <acronym>WebQuit Plus</acronym>
  <official_title>Web-Delivered Acceptance &amp; Commitment Therapy for Smokers With Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Palo Alto Veterans Institute for Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bedford Research Corporation, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jefferson Center, Community Mental Health Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Central Western Massachusetts Healthcare System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This purpose of the study is to develop and test a new website to help people who have
      bipolar disorder quit smoking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consist of two separate phases. Phase I consists of website usability testing.
      Investigators will collect feedback and incorporate the feedback into our website that is
      tailored for people with bipolar disorder. In Phase II investigators will be comparing quit
      rates of two groups both utilizing Nicotine Replacement Therapy and a website.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2017</start_date>
  <completion_date type="Actual">May 14, 2019</completion_date>
  <primary_completion_date type="Actual">May 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment</measure>
    <time_frame>Week -1 (Visit 0)</time_frame>
    <description>Number approached, screened, eligible, and consented; reasons for ineligibility or refusal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recruitment</measure>
    <time_frame>Week 0 (Visit 1)</time_frame>
    <description>Number approached, screened, eligible, and consented; reasons for ineligibility or refusal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Completion of the experimental intervention</measure>
    <time_frame>Week 10</time_frame>
    <description>Completion of the core treatment program</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention in study</measure>
    <time_frame>Week 10</time_frame>
    <description>Percentage of participants in each arm completing outcome assessments at end of treatment visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention in study</measure>
    <time_frame>Week 14</time_frame>
    <description>Percentage of participants in each arm completing outcome assessments at 1-month follow-up visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment satisfaction</measure>
    <time_frame>Week 10</time_frame>
    <description>12 item survey used in our prior work assessing satisfaction with the assigned treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment utilization</measure>
    <time_frame>Week 10</time_frame>
    <description>Server-recorded log-ins to the assigned treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in acceptance of smoking triggers</measure>
    <time_frame>Week 10</time_frame>
    <description>Change in acceptance scores between baseline and end of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in commitment to quit</measure>
    <time_frame>Week 10</time_frame>
    <description>Change in commitment scores between baseline and end of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CO-confirmed 7-day point prevalence abstinence from cigarette smoking</measure>
    <time_frame>Weeks 10</time_frame>
    <description>Preliminary efficacy for smoking cessation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CO-confirmed 7-day point prevalence abstinence from cigarette smoking</measure>
    <time_frame>Week 14</time_frame>
    <description>Preliminary efficacy for smoking cessation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in bipolar disorder symptoms</measure>
    <time_frame>Week 10</time_frame>
    <description>Change in mania and depression scale scores</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Smoking</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Experimental therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Experimental plus Nicotine Replacement Therapy</intervention_name>
    <description>Behavioral: Experimental plus Nicotine Replacement Therapy will be built to specifically address challenges of smoking cessation for individuals with bipolar disorder.
Includes four in person and four phone visits.
Therapy information is withheld to protect the integrity of the study.</description>
    <arm_group_label>Experimental therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control plus Nicotine Replacement Therapy</intervention_name>
    <description>Includes four in-person and four phone visits</description>
    <arm_group_label>Control Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 or older

          2. Daily smoker for the past year, averaging at least 5 cigarettes per day for the past
             30 days, with expired-air carbon monoxide (CO) level â‰¥ 4 ppm

          3. Motivated to quit smoking (i.e., endorse plans to quit in the next 30 days at the time
             of phone pre-screening)

          4. Meets lifetime criteria for bipolar I or II disorder, based on DSM-V criteria

          5. Willing to be randomly assigned to either treatment group

          6. Has at least weekly access to a high-speed Internet connection via a tablet, laptop or
             desktop computer

          7. Willing and able to read in English

          8. Is under care of a clinician for the treatment of bipolar disorder

          9. Willing to authorize communication with the clinician regarding study participation
             and clinical deterioration

         10. Willing to use the nicotine patch to help quit smoking

        Exclusion Criteria:

          1. Participating in other smoking cessation interventions

          2. Currently using any pharmacotherapies for smoking cessation

          3. Previous use of the Smokefree.gov website

          4. Meets DSM-V criteria for current mania

          5. Meets DSM-V criteria for a current major depressive episode and symptoms are currently
             severe (Patient Health Questionnaire-9 score &gt; 14)

          6. Current psychotic symptoms

          7. Psychiatric hospitalization within one month prior to enrollment

          8. Current suicidal or homicidal ideation

          9. Meets criteria for a DSM-V diagnosis of a moderate or severe substance use disorder in
             past month prior to enrollment

         10. Unstable medical condition

         11. Any medical or psychiatric condition that, in the opinion of the investigator, is
             severe enough to interfere with protocol adherence or ability to benefit from the
             intervention

         12. Any medical conditions that would preclude use of the nicotine patch (e.g., recent
             myocardial infarction, significant skin disorder, previous severe adverse reaction to
             nicotine patch, pregnant or breast feeding, assessed with our standard protocol for
             determining NRT eligibility)

         13. Employee or family member of the investigator or study center, or member of the same
             household as another research participant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaimee Heffner, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palo Alto Veterans Institute for Research</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jefferson Center for Mental Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bedford VA Research Corp</name>
      <address>
        <city>Bedford</city>
        <state>Massachusetts</state>
        <zip>01730</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Central Western Massachusetts Healthcare System</name>
      <address>
        <city>Leeds</city>
        <state>Massachusetts</state>
        <zip>01503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking Cessation</keyword>
  <keyword>Acceptance &amp; Commitment Therapy</keyword>
  <keyword>Cognitive Behavioral Therapy</keyword>
  <keyword>Bipolar Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

